Lycera Corp.

Resolution Therapeutics raises £63.5 million in Series B financing led by Syncona Ltd. to advance RTX001, a first-in-class macrophage therapy for end-stage liver disease, into Phase I/II EMERALD study. Proceeds also support manufacturing and pipeline expansion into other inflammatory and fibrotic diseases. Paul Sekhri appointed as Chair of the Board of Directors.